These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 3000263)

  • 1. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia.
    Mahley RW; Innerarity TL; Rall SC; Weisgraber KH
    Ann N Y Acad Sci; 1985; 454():209-21. PubMed ID: 3000263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia).
    Chappell DA
    J Clin Invest; 1989 Dec; 84(6):1906-15. PubMed ID: 2556448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherogenic lipoproteins resulting from genetic defects of apolipoproteins B and E.
    Weisgraber KH; Innerarity TL; Rall SC; Mahley RW
    Ann N Y Acad Sci; 1990; 598():37-48. PubMed ID: 2248450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E.
    Hui DY; Innerarity TL; Mahley RW
    J Biol Chem; 1984 Jan; 259(2):860-9. PubMed ID: 6319389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia.
    Ehnholm C; Mahley RW; Chappell DA; Weisgraber KH; Ludwig E; Witztum JL
    Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5566-70. PubMed ID: 6591204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phenocopy of type III dysbetalipoproteinemia occurring in a candidate family for a putative apo E receptor defect.
    Davignon J; Dallongeville J; Roederer G; Roy M; Fruchart JC; Kessling AM; Bouthillier D; Lussier-Cacan S
    Ann Med; 1991 Apr; 23(2):161-7. PubMed ID: 1648930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catabolism of very-low-density lipoproteins in subjects with broad beta disease: comparison with endogenous hypertriglyceridemia.
    Kushwaha RS; Chait A; Hazzard WR
    J Lab Clin Med; 1982 Jan; 99(1):15-24. PubMed ID: 6948063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of type III VLDL, their remnants, and VLDL from ApoE-knockout mice by p-hydroxyphenylacetaldehyde, a product of myeloperoxidase activity, causes marked cholesteryl ester accumulation in macrophages.
    Whitman SC; Hazen SL; Miller DB; Hegele RA; Heinecke JW; Huff MW
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1238-49. PubMed ID: 10323775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hereditary changes of apolipoproteins B and E].
    Gaeta G; Effuso L; Maurea N; Boccalatte M; Antignano A; Sifola C; Scala R
    Clin Ter; 1994 Jun; 144(6):527-37. PubMed ID: 8001338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Apolipoprotein E].
    Yamamura T
    Nihon Rinsho; 1994 Dec; 52(12):3124-32. PubMed ID: 7853700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS; Fazio S; Mahley RW
    J Biol Chem; 1994 May; 269(18):13421-8. PubMed ID: 8175773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia.
    Rall SC; Weisgraber KH; Innerarity TL; Mahley RW
    J Clin Invest; 1983 Apr; 71(4):1023-31. PubMed ID: 6300187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows.
    Schneider WJ; Kovanen PT; Brown MS; Goldstein JL; Utermann G; Weber W; Havel RJ; Kotite L; Kane JP; Innerarity TL; Mahley RW
    J Clin Invest; 1981 Oct; 68(4):1075-85. PubMed ID: 6270194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased binding of LDL and VLDL to apo B,E receptors of hepatic plasma membrane of rats treated with Fibernat.
    Venkatesan N; Devaraj SN; Devaraj H
    Eur J Nutr; 2003 Oct; 42(5):262-71. PubMed ID: 14569407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis.
    Huang Y; Schwendner SW; Rall SC; Sanan DA; Mahley RW
    J Biol Chem; 1997 Sep; 272(36):22685-94. PubMed ID: 9312550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis.
    Van Eck M; Herijgers N; Yates J; Pearce NJ; Hoogerbrugge PM; Groot PH; Van Berkel TJ
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3117-26. PubMed ID: 9409301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDL, VLDL, chylomicrons and atherosclerosis.
    Nordestgaard BG; Tybjaerg-Hansen A
    Eur J Epidemiol; 1992 May; 8 Suppl 1():92-8. PubMed ID: 1505659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of lipoprotein receptors in lipid transport and in the pathogenesis of the hyperlipoproteinemias.
    Chait A
    Spec Top Endocrinol Metab; 1983; 5():1-53. PubMed ID: 6322371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Apolipoprotein E and its alleles in healthy subjects and in atherosclerosis].
    Couderc R; Bailleul S
    Ann Biol Clin (Paris); 1998; 56(6):651-9. PubMed ID: 9853024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Physiology and pathophysiology of the metabolism of lipoproteins].
    Sandhofer F
    Wien Med Wochenschr; 1994; 144(12-13):286-90. PubMed ID: 8650930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.